Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective

Journal of Medical Economics

Volumn 12, Issue 3, 2009, Pages 246-258

  Bessette, Louis ^a   Risebrough, Nancy ^b   Mittmann, Nicole ^b   Roussy, Jean Pascal ^c   Ho, Joanne ^d   Zlateva, Gergana ^c  

^a LAVAL UNIVERSITY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c PFIZER INC   (United States)

^d Dymaxium Inc   (Canada)

Author keywords

Celecoxib; Cost effectiveness; Cost utility; NSAID; Osteoarthritis; Quebec; Rheumatoid arthritis

Indexed keywords

CELECOXIB; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ANALYTICAL RESEARCH; ARTICLE; CANADA; CARDIOVASCULAR SYSTEM; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEALTH CARE SYSTEM; HEART INFARCTION; HUMAN; OSTEOARTHRITIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; STROKE; ULCER; UPPER GASTROINTESTINAL TRACT;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL TRACT; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MARKOV CHAINS; MIDDLE AGED; OSTEOARTHRITIS; PYRAZOLES; QUALITY-ADJUSTED LIFE YEARS; QUEBEC; SULFONAMIDES;

EID: 75149146899     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903288970     Document Type: Article

References (57)

1. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-1155 (Pubitemid 37500619)
2. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-1915
3. Tannenbaum H, Bombardier C, Davis P, Russell AS. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-157
4. Maetzel A, Li LC, Pencharz J, et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401.
5. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-1255
6. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999;56:18-24.
7. Tamblyn R, Berkson L, Dauphinee WD, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997;127:429-438
8. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119:255-266
9. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644-65.
10. Goldstein JL, Eisen G, Stenson W, et al. Celecoxib significantly reduces gastrointestinal-related healthcare resource utilization compared to NSAIDs: SUCCESS-1 in osteoarthritis (OA) trial. Arthritis Rheum 2001;44(Suppl):503
11. Goldstein JL, Zhao SZ, Burke TA, et al. Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States. Am J Gastroenterol 2003;98:2627-2634
12. Rahme E, Barkun AN, Adam V, Bardou M. Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs. Drug Saf 2004;27:1019-1042
13. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102
14. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080
15. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-1308
16. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-1644
17. Zabinski RA, Burke TA, Johnson J, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001;19(Suppl 1):49-58.
18. Niculescu L, Lising A, Neumann PJ. Cost-utility outcomes simulation model for osteoarthritis (OA) and rheumatoid arthritis (RA) patients (COSMO): development and validation of a pharmacoeconomic model [abstract]. Value Health 2004;7:668.
19. Fries JF, Murtagh KN, Bennett M, et al. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004;50:2433-2440
20. Laine L. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Disord 2003;3(Suppl 4):S30-9.
21. Scheiman JM, Fendrick AM. Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs. Arthritis Res Ther 2005;7(Suppl 4):S23-9.
22. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-1012
23. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-796
24. Rahme E, Watson DJ, Kong SX, et al. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2007;16:493-503.
25. Health Canada. Arthritis in Canada. An Ongoing Challenge. Ottawa: Health Canada, 2003.
26. Moride Y, Ducruet T, Boivin JF, et al. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines. Can J Clin Pharmacol 2005;12:e201-e211.
27. McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-18.
28. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-1105
29. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-2111
30. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-1928
31. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
32. Simon LS, White WB, MacDonald TM, et al. Cardiovascular safety of celecoxib: a meta-analysis of 41 clinical studies in 44,300 patients [abstract]. Arthritis Rheum 2005;52(Suppl 9):S406-7.
33. White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007;99:91-98
34. Maetzel A, Krahn M, Naglie G. The cost-effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003;49:283-292
35. Wilcox CM, Clark WS. Association of nonsteroidal antiinflammatory drugs with outcome in upper and lower gastrointestinal bleeding. Dig Dis Sci 1997;42:985-989
36. Schaffer D, Florin T, Eagle C, et al. Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review. Med J Aust 2006;185:501-506
37. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-884
38. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-2110
39. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007;369:1621-1626
40. Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol 2006;47(Suppl 1):S60-6.
41. CANSIM Deaths, by cause: Diseases of the circulatory system, age group and sex (Canada, annual). Statistics Canada Web site. Available at: http://www.statcan.gc.ca. [Last accessed 4 March 2009].
42. Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999;15:369-376
43. Kristiansen IS, Kvien TK. Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis. Expert Rev Pharmacoeconomics Outcomes Res 2002;2:229-241
44. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003;21:191-200.
45. Régie de l'assurance maladie du Québec (RAMQ). Studies and Statistics. RAMQ Web site. Available at: http:www.ramq.gouv.qc.ca/en/ statistiques/index.shtml. [Last accessed 12 March 2009].
46. Lamy A, Yusuf S, Pogue J, Gafni A. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003;107:960-965 (Pubitemid 36258717)
47. Casciano R, Tarride JE, Breton MC, et al. A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in Canada. Can J Clin Pharmacol 2004;11:e179-90.
48. Bank of Canada. Consumer Price Index: Rates and Statistics. Bank of Canada Web site. Available at: http://www.bankofcanada.ca/en/rates/inflation- calc.html. [Last accessed 12 March 2009].
49. Soto J, Romero AB, Rejas J. Analisis farmacoeconomico del uso de celecoxib en el tratamiento de la artrosis. Rev Esp Reumatol 2002;29:142-150
50. Moreno A, Vargas E, Soto J, Rejas J. Cost-effectiveness analysis of the use of celecoxib for the treatment of osteoarthritis [in Spanish]. Gac Sanit 2003;17:27-36.
51. Rahme E, Toubouti Y, LeLorier J. Utilization and cost comparison of current and optimal prescribing of nonsteroidal antiinflammatory drugs in Quebec, Canada. J Rheumatol 2006;33:588-596
52. Goldstein JL, Howard KB, Walton SM, et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006;4:1337-1345
53. Moore RA, Derry S, Phillips CJ, McQuay HJ. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006;7:79.
54. Sturkenboom MC, Burke TA, Tangelder MJ, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003;18:1137-1147
55. Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003;42(Suppl 3):iii23-31.
56. Koncz TA, Lister SP, Makinson GT. Gastroprotection in patients prescribed non-selective NSAIDs, and the risk of related hospitalization. Curr Med Res Opin 2008;24:3405-3412
57. Depont F, Fourrier A, Merliere Y, et al. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CANEUS) study. Pharmacoepidemiol Drug Saf 2007;16:891-900.